SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer (TORCH-STAR)
SCRT Followed by CAPOX and PD-1 Inhibitor Versus LCCRT Followed by CAPOX in Total Neoadjuvant Treatment for High-risk LARC: A Prospective, Randomized, Multicenter, Phase III Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Zhen Zhang, MD, PhD
- Phone Number: 18801735029
- Email: zhen_zhang@fudan.edu.cn
Study Locations
-
-
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
Contact:
- Zhen Zhang, MD, PhD
- Phone Number: 18801735029
- Email: zhen_zhang@fudan.edu.cn
-
Contact:
- Yaqi Wang, MD
- Phone Number: 18121299593
- Email: 10301010093@fudan.edu.cn
-
Principal Investigator:
- Zhen Zhang, MD PhD
-
Principal Investigator:
- Xinxiang Li, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age 18-75 years old, female and male;
- Pathological confirmed adenocarcinoma;
- The distance from anal verge ≤ 10 cm;
- MSI/MMR status: MSS/pMMR;
- Clinical stage T3-4 and/or N+, without distance metastases;
- At least one of the following factors is present: distance from the anus ≤5 cm, cT4, cN2, positive cMRF, positive cEMVI, positive tumor deposit or positive lateral lymph node;
- KPS ≥ 70;
- No radiotherapy, chemotherapy, immunotherapy, or any other anti-tumor therapy had been administered prior to enrollment;
- Baseline blood and biochemical indicators meet the following criteria: neutrophils ≥ 1.5 × 10^9/L, Hb ≥ 90 g/L, PLT ≥ 100 × 10^9/L, ALT/ AST ≤ 2.5 ULN, Cr ≤ 1 ULN;
- With good compliance and signed the consent form.
Exclusion Criteria
- Pregnancy or breast-feeding women;
- Known history of other malignancies within 5 years;
- Known history of severe neurological or mental illness (such as schizophrenia, dementia or epilepsy);
- Current severe cardiac disease (cardiac dysfunction and arrhythmia), renal dysfunction and liver dysfunction;
- Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment;
- Uncontrolled infection which needs systemic therapy;
- Active autoimmune disease or immunodeficiencies, known history of organ transplantation or systematic use of immunosuppressive agents;
- Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1 to 2 antibody positive), active syphilis infection, active pulmonary tuberculosis infection;
- Allergic to any component of the therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: TNT group
TNT group receives long-course chemoradiotherapy (concurrent with oral capecitabine) followed by 6 cycles of CAPOX.
|
Capecitabine: 1000mg/m2 bid d1-14 q3w
Oxaliplatin 130mg/m2 d1 q3w
long-course chemoradiotherapy (50Gy/25Fx concurrent with oral capecitabine 825mg/m2 bid d1-5 qw)
|
|
Experimental: iTNT group
iTNT group receives short-course radiotherapy (25Gy/5Fx) followed by 6 cycles of Serplulimab combined with CAPOX.
|
Capecitabine: 1000mg/m2 bid d1-14 q3w
Oxaliplatin 130mg/m2 d1 q3w
short-course radiaotherapy (25Gy/5Fx)
Serplulimab 300mg d1 q3w
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3 year event-free survival rate
Time Frame: From date of randomization until the date of first documented early local failure, disease progression during neoadjuvant therapy, pelvic recurrence, distant metastasis, or death, whichever came first, assessed up to 36 months.
|
Rate of 3 year event free survival
|
From date of randomization until the date of first documented early local failure, disease progression during neoadjuvant therapy, pelvic recurrence, distant metastasis, or death, whichever came first, assessed up to 36 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3 year overall survival rate
Time Frame: From date of randomization until the date of death from any cause, assessed up to 36 months.
|
Rate of 3 year overall survival
|
From date of randomization until the date of death from any cause, assessed up to 36 months.
|
|
3 year local recurrence free survival rate
Time Frame: From date of randomization until the date of first documented pelvic failure, assessed up to 36 months.
|
Rate of 3 year local recurrence free survival
|
From date of randomization until the date of first documented pelvic failure, assessed up to 36 months.
|
|
Complete response (CR) rate
Time Frame: 1 month after the surgery or the decision of W&W
|
Rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W&W strategy.
|
1 month after the surgery or the decision of W&W
|
|
Grade 3-4 adverse effects rate
Time Frame: From date of randomization until 3 months after the completion neoadjuvant therapy
|
Rate of chemotherapy, radiotherapy and immunotherapy related adverse events
|
From date of randomization until 3 months after the completion neoadjuvant therapy
|
|
3 year distant metastasis free survival rate
Time Frame: From date of randomization until the date of first documented distant metastasis, assessed up to 36 months.
|
Rate of 3 year distant metastasis free survival
|
From date of randomization until the date of first documented distant metastasis, assessed up to 36 months.
|
|
3 year organ preservation rate
Time Frame: From date of randomization until the resection of rectum or anus, assessed up to 36 months.
|
3 year organ preservation rate
|
From date of randomization until the resection of rectum or anus, assessed up to 36 months.
|
|
3 year disease free survival rate
Time Frame: From date of randomization until the date of first documented recurrence and metastasis after the completion of treatment or death from any cause, whichever came first, assessed up to 36 months.
|
Rate of 3 year disease free survival
|
From date of randomization until the date of first documented recurrence and metastasis after the completion of treatment or death from any cause, whichever came first, assessed up to 36 months.
|
|
Rate of surgical complications
Time Frame: The surgical complications were assessed within 1 year after the surgery.
|
Rate of surgical complications
|
The surgical complications were assessed within 1 year after the surgery.
|
|
Low Anterior Resection Syndrome Score
Time Frame: From date of randomization until five years after the completion of treament.
|
Evaluating the anal function using Low Anterior Resection Syndrome (LARS) score(range 0-42, with higher scores representing worse anal function)
|
From date of randomization until five years after the completion of treament.
|
|
Wexner Continence Grading Scale
Time Frame: From date of randomization until five years after the completion of treament.
|
Evaluating the anal function using Wexner Continence Grading Scale (range 1-20, with higher scores representing worse anal function)
|
From date of randomization until five years after the completion of treament.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Spinal Cord Diseases
- Cerebellar Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Spinocerebellar Degenerations
- Antineoplastic Agents, Immunological
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Nucleic Acids, Nucleotides, and Nucleosides
- Pharmacologic Actions
- Chemical Actions and Uses
- Therapeutic Uses
- Coordination Complexes
- Deoxycytidine
- Cytidine
- Pyrimidine Nucleosides
- Pyrimidines
- Nucleosides
- Uracil
- Pyrimidinones
- Deoxyribonucleosides
- Fluorouracil
- Capecitabine
- Oxaliplatin
- Immune Checkpoint Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- FDRT-2025-665-4814
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.